| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 114 | 2019 | 1155 | 5.540 |
Why?
|
| Islets of Langerhans | 39 | 2012 | 546 | 2.450 |
Why?
|
| Insulin | 60 | 2021 | 1152 | 2.300 |
Why?
|
| Polymorphism, Genetic | 41 | 2007 | 824 | 1.940 |
Why?
|
| Calpain | 23 | 2010 | 111 | 1.750 |
Why?
|
| Diabetes Mellitus | 20 | 2021 | 742 | 1.700 |
Why?
|
| Receptors, Somatostatin | 26 | 1997 | 33 | 1.650 |
Why?
|
| Mutation | 49 | 2021 | 4061 | 1.630 |
Why?
|
| Transcription Factors | 30 | 2018 | 1619 | 1.590 |
Why?
|
| DNA-Binding Proteins | 25 | 2005 | 1224 | 1.520 |
Why?
|
| Insulin-Secreting Cells | 17 | 2021 | 401 | 1.510 |
Why?
|
| Base Sequence | 88 | 2011 | 2331 | 1.400 |
Why?
|
| Molecular Sequence Data | 100 | 2010 | 3028 | 1.360 |
Why?
|
| Chromosome Mapping | 42 | 2019 | 1076 | 1.270 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 19 | 1996 | 135 | 1.270 |
Why?
|
| Glucokinase | 24 | 2010 | 61 | 1.220 |
Why?
|
| Genetic Variation | 26 | 2017 | 1365 | 1.180 |
Why?
|
| Diabetes Mellitus, Type 1 | 18 | 2016 | 559 | 1.110 |
Why?
|
| Proinsulin | 10 | 2017 | 124 | 1.040 |
Why?
|
| Nuclear Proteins | 14 | 2005 | 720 | 1.040 |
Why?
|
| Phosphoproteins | 11 | 2009 | 257 | 1.000 |
Why?
|
| Trans-Activators | 9 | 2018 | 436 | 0.990 |
Why?
|
| Pedigree | 46 | 2017 | 968 | 0.940 |
Why?
|
| Infant, Newborn, Diseases | 5 | 2013 | 111 | 0.940 |
Why?
|
| Blood Glucose | 28 | 2015 | 838 | 0.910 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 11 | 2013 | 30 | 0.860 |
Why?
|
| Genetic Predisposition to Disease | 26 | 2017 | 2306 | 0.840 |
Why?
|
| Animals | 124 | 2019 | 26951 | 0.800 |
Why?
|
| Monosaccharide Transport Proteins | 15 | 2004 | 73 | 0.800 |
Why?
|
| Humans | 232 | 2021 | 87552 | 0.750 |
Why?
|
| Promoter Regions, Genetic | 16 | 2013 | 951 | 0.740 |
Why?
|
| Mutation, Missense | 10 | 2014 | 276 | 0.740 |
Why?
|
| RNA, Messenger | 40 | 2014 | 1994 | 0.740 |
Why?
|
| Chromosomes, Human, Pair 20 | 10 | 1996 | 32 | 0.730 |
Why?
|
| Transgenes | 5 | 2013 | 181 | 0.720 |
Why?
|
| DNA | 27 | 2007 | 1305 | 0.720 |
Why?
|
| Glucose | 24 | 2014 | 626 | 0.710 |
Why?
|
| Homeodomain Proteins | 7 | 2014 | 544 | 0.690 |
Why?
|
| Diabetes Mellitus, Experimental | 7 | 2015 | 189 | 0.690 |
Why?
|
| Polymerase Chain Reaction | 41 | 2002 | 925 | 0.670 |
Why?
|
| Insulin Resistance | 14 | 2017 | 361 | 0.660 |
Why?
|
| Amino Acid Sequence | 45 | 2010 | 2061 | 0.650 |
Why?
|
| Chromosomes, Human, Pair 2 | 7 | 2002 | 85 | 0.640 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 13 | 2011 | 120 | 0.610 |
Why?
|
| Regeneration | 5 | 2016 | 147 | 0.610 |
Why?
|
| Male | 129 | 2019 | 41500 | 0.610 |
Why?
|
| Cloning, Molecular | 30 | 2005 | 647 | 0.600 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 8 | 2002 | 122 | 0.590 |
Why?
|
| Gene Expression Regulation | 16 | 2017 | 1956 | 0.590 |
Why?
|
| Potassium Channels | 12 | 2007 | 343 | 0.570 |
Why?
|
| Mice | 55 | 2019 | 11586 | 0.570 |
Why?
|
| Female | 125 | 2019 | 45189 | 0.560 |
Why?
|
| DNA Primers | 28 | 2002 | 544 | 0.540 |
Why?
|
| Mice, Transgenic | 16 | 2014 | 1563 | 0.540 |
Why?
|
| Liver | 13 | 2017 | 1235 | 0.530 |
Why?
|
| Alleles | 27 | 2017 | 1128 | 0.520 |
Why?
|
| Hexokinase | 6 | 1997 | 19 | 0.510 |
Why?
|
| Exons | 18 | 2015 | 450 | 0.480 |
Why?
|
| Receptors, Opioid, kappa | 7 | 1994 | 15 | 0.480 |
Why?
|
| Calcium Channels | 9 | 1996 | 182 | 0.480 |
Why?
|
| Mexican Americans | 10 | 2017 | 66 | 0.460 |
Why?
|
| Infant, Newborn | 22 | 2021 | 2425 | 0.460 |
Why?
|
| In Situ Hybridization, Fluorescence | 19 | 2000 | 353 | 0.450 |
Why?
|
| Genetic Markers | 22 | 2000 | 476 | 0.450 |
Why?
|
| Gene Expression | 15 | 2014 | 1296 | 0.440 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2005 | 308 | 0.440 |
Why?
|
| Obesity | 10 | 2016 | 955 | 0.440 |
Why?
|
| Islets of Langerhans Transplantation | 2 | 2012 | 240 | 0.430 |
Why?
|
| Rats | 31 | 2017 | 4013 | 0.430 |
Why?
|
| Oligodeoxyribonucleotides | 16 | 1996 | 126 | 0.430 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2012 | 14 | 0.420 |
Why?
|
| Polymorphism, Single Nucleotide | 15 | 2019 | 2385 | 0.420 |
Why?
|
| Genetic Linkage | 26 | 2007 | 623 | 0.410 |
Why?
|
| Gene Frequency | 18 | 2019 | 682 | 0.410 |
Why?
|
| Genome-Wide Association Study | 13 | 2019 | 1648 | 0.410 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 14 | 2014 | 80 | 0.410 |
Why?
|
| Fetal Blood | 1 | 2012 | 89 | 0.400 |
Why?
|
| Polycystic Ovary Syndrome | 5 | 2009 | 204 | 0.400 |
Why?
|
| Point Mutation | 13 | 2013 | 247 | 0.400 |
Why?
|
| Adult | 73 | 2019 | 26016 | 0.390 |
Why?
|
| Amino Acid Substitution | 10 | 2013 | 336 | 0.390 |
Why?
|
| Receptors, Cell Surface | 4 | 1997 | 289 | 0.390 |
Why?
|
| Organ Specificity | 16 | 2012 | 263 | 0.390 |
Why?
|
| Chromosomes, Human, Pair 19 | 4 | 1995 | 59 | 0.380 |
Why?
|
| Glucose Tolerance Test | 17 | 2010 | 227 | 0.380 |
Why?
|
| DNA, Complementary | 13 | 2002 | 394 | 0.380 |
Why?
|
| Japan | 13 | 2005 | 303 | 0.380 |
Why?
|
| Pancreas | 6 | 2018 | 242 | 0.370 |
Why?
|
| Brain Chemistry | 5 | 1994 | 122 | 0.370 |
Why?
|
| Genotype | 22 | 2017 | 1862 | 0.370 |
Why?
|
| Chromosomes, Human, Pair 6 | 6 | 2010 | 125 | 0.370 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 15 | 2007 | 34 | 0.370 |
Why?
|
| Codon, Nonsense | 2 | 2007 | 42 | 0.370 |
Why?
|
| Genes | 7 | 2004 | 305 | 0.360 |
Why?
|
| Exome | 5 | 2019 | 127 | 0.360 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 4 | 2014 | 29 | 0.350 |
Why?
|
| Introns | 12 | 2015 | 294 | 0.350 |
Why?
|
| Luminescent Measurements | 2 | 2013 | 62 | 0.350 |
Why?
|
| Carrier Proteins | 8 | 2013 | 677 | 0.350 |
Why?
|
| Receptors, Drug | 8 | 2011 | 54 | 0.340 |
Why?
|
| Endoplasmic Reticulum | 2 | 2009 | 253 | 0.340 |
Why?
|
| Muscle, Skeletal | 8 | 2007 | 461 | 0.330 |
Why?
|
| Piperidines | 2 | 2013 | 163 | 0.330 |
Why?
|
| ATP-Binding Cassette Transporters | 8 | 2011 | 141 | 0.330 |
Why?
|
| Somatostatin | 12 | 1997 | 55 | 0.330 |
Why?
|
| Hepatocyte Nuclear Factor 6 | 2 | 2007 | 5 | 0.330 |
Why?
|
| Chromosomes, Human, Pair 17 | 3 | 1994 | 110 | 0.330 |
Why?
|
| Adaptation, Biological | 1 | 2009 | 85 | 0.330 |
Why?
|
| Haplotypes | 15 | 2014 | 637 | 0.320 |
Why?
|
| Diagnostic Imaging | 2 | 2010 | 474 | 0.310 |
Why?
|
| Fetal Macrosomia | 1 | 2007 | 10 | 0.310 |
Why?
|
| Nerve Tissue Proteins | 2 | 2001 | 507 | 0.310 |
Why?
|
| Pregnancy, Animal | 2 | 1997 | 58 | 0.300 |
Why?
|
| Chromosomes, Human, Pair 13 | 3 | 2000 | 51 | 0.300 |
Why?
|
| Genetic Testing | 7 | 2013 | 534 | 0.300 |
Why?
|
| Quantitative Trait Loci | 5 | 2018 | 601 | 0.300 |
Why?
|
| Hypoglycemia | 2 | 2007 | 105 | 0.300 |
Why?
|
| Cell Line | 20 | 2017 | 2488 | 0.300 |
Why?
|
| Multigene Family | 7 | 2003 | 199 | 0.290 |
Why?
|
| Age of Onset | 10 | 2021 | 311 | 0.290 |
Why?
|
| Monitoring, Physiologic | 1 | 2008 | 264 | 0.290 |
Why?
|
| Models, Genetic | 4 | 2009 | 937 | 0.290 |
Why?
|
| Biological Evolution | 2 | 2009 | 934 | 0.290 |
Why?
|
| Metabolome | 2 | 2019 | 50 | 0.290 |
Why?
|
| Adipose Tissue | 5 | 2017 | 246 | 0.280 |
Why?
|
| Sequence Homology, Amino Acid | 12 | 1997 | 416 | 0.280 |
Why?
|
| Chromosomes, Human, Pair 8 | 3 | 2003 | 85 | 0.280 |
Why?
|
| In Situ Hybridization | 12 | 2004 | 310 | 0.280 |
Why?
|
| Adenylyl Cyclases | 7 | 1994 | 100 | 0.280 |
Why?
|
| Chromosomes, Human, Pair 1 | 4 | 2004 | 100 | 0.270 |
Why?
|
| Luminescent Agents | 1 | 2005 | 6 | 0.270 |
Why?
|
| Receptors, Glucagon | 3 | 2015 | 11 | 0.270 |
Why?
|
| Luciferases, Firefly | 1 | 2005 | 12 | 0.270 |
Why?
|
| Phenotype | 16 | 2019 | 2415 | 0.270 |
Why?
|
| Hepatocyte Nuclear Factor 1 | 12 | 2004 | 30 | 0.270 |
Why?
|
| Cell Nucleolus | 1 | 2005 | 23 | 0.260 |
Why?
|
| Luciferases | 4 | 2013 | 126 | 0.260 |
Why?
|
| Glycogen Synthase | 3 | 1996 | 22 | 0.260 |
Why?
|
| Saccharomyces cerevisiae | 3 | 1997 | 435 | 0.250 |
Why?
|
| Hypoglycemic Agents | 7 | 2013 | 342 | 0.250 |
Why?
|
| Proteins | 5 | 1997 | 784 | 0.250 |
Why?
|
| Chromosomes, Human, Pair 7 | 6 | 1996 | 79 | 0.250 |
Why?
|
| Apoptosis | 3 | 2014 | 1703 | 0.250 |
Why?
|
| Case-Control Studies | 12 | 2019 | 1834 | 0.250 |
Why?
|
| Genome, Human | 7 | 2007 | 766 | 0.240 |
Why?
|
| Fentanyl | 1 | 2004 | 66 | 0.240 |
Why?
|
| Middle Aged | 52 | 2019 | 25341 | 0.240 |
Why?
|
| C-Peptide | 9 | 2017 | 179 | 0.240 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2003 | 181 | 0.240 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2018 | 219 | 0.240 |
Why?
|
| Morphine | 1 | 2004 | 130 | 0.230 |
Why?
|
| Fasting | 3 | 2017 | 163 | 0.230 |
Why?
|
| Luminescent Proteins | 2 | 2002 | 144 | 0.220 |
Why?
|
| Stress, Physiological | 1 | 2004 | 230 | 0.220 |
Why?
|
| Hybrid Cells | 8 | 1995 | 71 | 0.220 |
Why?
|
| Membrane Proteins | 3 | 2014 | 1210 | 0.210 |
Why?
|
| Chromosomes, Human, Pair 11 | 4 | 2003 | 106 | 0.210 |
Why?
|
| Child | 23 | 2021 | 7039 | 0.210 |
Why?
|
| Glucose Intolerance | 3 | 2014 | 94 | 0.210 |
Why?
|
| Linkage Disequilibrium | 7 | 2016 | 474 | 0.210 |
Why?
|
| Genetic Therapy | 2 | 2010 | 353 | 0.210 |
Why?
|
| Sulfonylurea Receptors | 8 | 2011 | 50 | 0.210 |
Why?
|
| Body Mass Index | 7 | 2019 | 762 | 0.200 |
Why?
|
| Pain | 1 | 2004 | 396 | 0.200 |
Why?
|
| Enhancer Elements, Genetic | 3 | 2012 | 277 | 0.200 |
Why?
|
| Frameshift Mutation | 3 | 2013 | 50 | 0.200 |
Why?
|
| Transfection | 10 | 2005 | 907 | 0.200 |
Why?
|
| Sulfonylurea Compounds | 6 | 2013 | 62 | 0.200 |
Why?
|
| Inositol 1,4,5-Trisphosphate | 4 | 1996 | 28 | 0.190 |
Why?
|
| Insulin-Like Growth Factor II | 3 | 2017 | 33 | 0.190 |
Why?
|
| Helix-Loop-Helix Motifs | 1 | 2000 | 25 | 0.190 |
Why?
|
| Adenosine Triphosphate | 6 | 2005 | 314 | 0.190 |
Why?
|
| Adolescent | 30 | 2019 | 9079 | 0.190 |
Why?
|
| Dinucleotide Repeats | 2 | 1997 | 13 | 0.180 |
Why?
|
| Analgesics, Opioid | 1 | 2004 | 432 | 0.180 |
Why?
|
| Infant | 10 | 2021 | 3098 | 0.180 |
Why?
|
| Fibrosarcoma | 1 | 2000 | 85 | 0.180 |
Why?
|
| Michigan | 2 | 2011 | 53 | 0.180 |
Why?
|
| GTP-Binding Proteins | 7 | 1994 | 147 | 0.170 |
Why?
|
| Chromosomes, Artificial, Yeast | 5 | 1996 | 37 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 16 | 2 | 2000 | 79 | 0.170 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2004 | 472 | 0.170 |
Why?
|
| Receptors, Muscarinic | 2 | 2002 | 49 | 0.170 |
Why?
|
| Aged | 28 | 2019 | 18642 | 0.170 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2000 | 114 | 0.170 |
Why?
|
| Calcium | 12 | 2005 | 1170 | 0.170 |
Why?
|
| One Health | 1 | 2019 | 2 | 0.170 |
Why?
|
| Salmonella | 1 | 2019 | 14 | 0.170 |
Why?
|
| Salmonella Infections, Animal | 1 | 2019 | 11 | 0.170 |
Why?
|
| Water Microbiology | 1 | 2018 | 13 | 0.170 |
Why?
|
| Muscles | 4 | 2000 | 193 | 0.170 |
Why?
|
| Water Wells | 1 | 2018 | 18 | 0.170 |
Why?
|
| Salmonella Infections | 1 | 2019 | 18 | 0.170 |
Why?
|
| Water Pollution, Chemical | 1 | 2018 | 21 | 0.170 |
Why?
|
| Heat-Shock Proteins | 1 | 2000 | 181 | 0.170 |
Why?
|
| Sequence Homology, Nucleic Acid | 5 | 2004 | 173 | 0.170 |
Why?
|
| Cells, Cultured | 8 | 2012 | 2842 | 0.170 |
Why?
|
| Cell Count | 3 | 2016 | 197 | 0.170 |
Why?
|
| Brain | 6 | 1996 | 2245 | 0.160 |
Why?
|
| Environmental Monitoring | 1 | 2018 | 71 | 0.160 |
Why?
|
| Hyperglycemia | 6 | 2006 | 169 | 0.160 |
Why?
|
| Cytoplasmic Granules | 3 | 1995 | 96 | 0.160 |
Why?
|
| Phosphatidylcholines | 1 | 2018 | 48 | 0.160 |
Why?
|
| Sleep, REM | 1 | 2018 | 50 | 0.160 |
Why?
|
| Gene Library | 6 | 1997 | 132 | 0.160 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 6 | 2004 | 54 | 0.160 |
Why?
|
| Genetic Association Studies | 2 | 2019 | 294 | 0.160 |
Why?
|
| Cricetinae | 15 | 2017 | 561 | 0.150 |
Why?
|
| Forecasting | 1 | 2019 | 303 | 0.150 |
Why?
|
| Imidazolines | 1 | 1997 | 6 | 0.150 |
Why?
|
| Sequence Analysis, DNA | 6 | 2015 | 860 | 0.150 |
Why?
|
| Sex | 1 | 1997 | 6 | 0.150 |
Why?
|
| Isoenzymes | 3 | 2001 | 272 | 0.150 |
Why?
|
| Leukemia, Myeloid | 2 | 1996 | 249 | 0.150 |
Why?
|
| Genes, Regulator | 1 | 1997 | 65 | 0.150 |
Why?
|
| RNA Splice Sites | 1 | 2017 | 55 | 0.150 |
Why?
|
| Fatty Acids | 1 | 2018 | 130 | 0.150 |
Why?
|
| Mass Spectrometry | 1 | 2018 | 189 | 0.150 |
Why?
|
| Water Pollutants, Chemical | 1 | 2018 | 135 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 9 | 2 | 1995 | 86 | 0.150 |
Why?
|
| Myometrium | 1 | 1997 | 49 | 0.150 |
Why?
|
| Child, Preschool | 7 | 2021 | 3652 | 0.150 |
Why?
|
| Neoplasm Proteins | 2 | 2000 | 539 | 0.150 |
Why?
|
| Protein Conformation | 3 | 1994 | 882 | 0.140 |
Why?
|
| Alternative Splicing | 3 | 2002 | 204 | 0.140 |
Why?
|
| Neisseria gonorrhoeae | 3 | 2003 | 16 | 0.140 |
Why?
|
| Protein Folding | 4 | 2013 | 282 | 0.140 |
Why?
|
| Gonorrhea | 3 | 2003 | 18 | 0.140 |
Why?
|
| Calcium-Binding Proteins | 2 | 2009 | 121 | 0.140 |
Why?
|
| Trinucleotide Repeats | 1 | 1996 | 32 | 0.140 |
Why?
|
| Transcription, Genetic | 10 | 2006 | 1143 | 0.140 |
Why?
|
| Restriction Mapping | 7 | 1996 | 157 | 0.140 |
Why?
|
| Retroelements | 1 | 1996 | 44 | 0.140 |
Why?
|
| Disease Susceptibility | 7 | 2013 | 197 | 0.140 |
Why?
|
| Neurosecretory Systems | 2 | 1995 | 36 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 1996 | 109 | 0.140 |
Why?
|
| Pregnancy | 9 | 2007 | 2969 | 0.140 |
Why?
|
| Cyclic AMP | 11 | 1995 | 274 | 0.140 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 3 | 2003 | 168 | 0.140 |
Why?
|
| Kidney | 6 | 1997 | 1140 | 0.140 |
Why?
|
| Reference Values | 9 | 2009 | 664 | 0.140 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2016 | 69 | 0.140 |
Why?
|
| Receptors, Pituitary Hormone | 2 | 1995 | 2 | 0.130 |
Why?
|
| Receptors, Gastrointestinal Hormone | 1 | 1995 | 5 | 0.130 |
Why?
|
| Embryo, Mammalian | 2 | 2007 | 222 | 0.130 |
Why?
|
| Uterus | 1 | 1997 | 217 | 0.130 |
Why?
|
| Texas | 6 | 2016 | 105 | 0.130 |
Why?
|
| Arsenic | 1 | 2018 | 255 | 0.130 |
Why?
|
| Carrier State | 1 | 2015 | 39 | 0.130 |
Why?
|
| Insulin, Regular, Human | 1 | 2015 | 6 | 0.130 |
Why?
|
| Receptors, Purinergic P2 | 1 | 1995 | 16 | 0.130 |
Why?
|
| Epilepsy | 4 | 2010 | 414 | 0.130 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1996 | 158 | 0.130 |
Why?
|
| Chromosomes, Human | 1 | 1995 | 66 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 334 | 0.130 |
Why?
|
| Glucose-6-Phosphatase | 1 | 2015 | 8 | 0.130 |
Why?
|
| Deoxyglucose | 3 | 2001 | 36 | 0.130 |
Why?
|
| Binding Sites | 10 | 2006 | 1107 | 0.130 |
Why?
|
| Nose | 1 | 2015 | 94 | 0.130 |
Why?
|
| Eating | 1 | 1996 | 165 | 0.130 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2016 | 105 | 0.130 |
Why?
|
| Myoblasts | 2 | 2005 | 32 | 0.130 |
Why?
|
| Heterozygote | 5 | 2013 | 367 | 0.130 |
Why?
|
| DNA Mutational Analysis | 5 | 2016 | 531 | 0.130 |
Why?
|
| Muscle Proteins | 4 | 2004 | 133 | 0.130 |
Why?
|
| Aorta | 1 | 2016 | 282 | 0.120 |
Why?
|
| Hypertriglyceridemia | 1 | 2015 | 68 | 0.120 |
Why?
|
| Blotting, Western | 6 | 2017 | 793 | 0.120 |
Why?
|
| Protein Binding | 5 | 2006 | 1475 | 0.120 |
Why?
|
| Green Fluorescent Proteins | 3 | 2005 | 307 | 0.120 |
Why?
|
| Mice, SCID | 2 | 2012 | 261 | 0.120 |
Why?
|
| Oocytes | 5 | 1996 | 221 | 0.120 |
Why?
|
| Hepatocytes | 2 | 2006 | 127 | 0.120 |
Why?
|
| Hominidae | 1 | 1995 | 97 | 0.120 |
Why?
|
| Receptors, Opioid, delta | 4 | 1994 | 7 | 0.120 |
Why?
|
| Recombinant Proteins | 12 | 2012 | 1020 | 0.120 |
Why?
|
| Genetic Loci | 2 | 2012 | 252 | 0.120 |
Why?
|
| Energy Metabolism | 3 | 2013 | 277 | 0.120 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2014 | 653 | 0.120 |
Why?
|
| Receptors, Opioid | 1 | 1993 | 23 | 0.120 |
Why?
|
| Evolution, Molecular | 2 | 1997 | 828 | 0.120 |
Why?
|
| CHO Cells | 12 | 1997 | 187 | 0.120 |
Why?
|
| Male Urogenital Diseases | 1 | 2013 | 9 | 0.120 |
Why?
|
| Metabolic Syndrome | 2 | 2005 | 128 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 2 | 2013 | 453 | 0.120 |
Why?
|
| Bone Development | 1 | 2013 | 35 | 0.110 |
Why?
|
| Digestive System | 1 | 1993 | 42 | 0.110 |
Why?
|
| Microcephaly | 1 | 2013 | 76 | 0.110 |
Why?
|
| Tissue Distribution | 6 | 1995 | 292 | 0.110 |
Why?
|
| Uracil | 1 | 2013 | 56 | 0.110 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2013 | 68 | 0.110 |
Why?
|
| Genomic Library | 4 | 2012 | 33 | 0.110 |
Why?
|
| Phosphoenolpyruvate Carboxykinase (GTP) | 1 | 1993 | 8 | 0.110 |
Why?
|
| Epilepsy, Generalized | 1 | 2013 | 39 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 1993 | 44 | 0.110 |
Why?
|
| HeLa Cells | 2 | 2004 | 503 | 0.110 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2014 | 200 | 0.110 |
Why?
|
| Thiazolidinediones | 1 | 2013 | 73 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 1993 | 49 | 0.110 |
Why?
|
| RNA | 2 | 1995 | 571 | 0.110 |
Why?
|
| KATP Channels | 2 | 2010 | 19 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 12 | 3 | 1997 | 65 | 0.110 |
Why?
|
| Staphylococcal Infections | 1 | 2015 | 267 | 0.110 |
Why?
|
| Immunohistochemistry | 4 | 2012 | 1779 | 0.110 |
Why?
|
| Inflammation | 2 | 2015 | 948 | 0.110 |
Why?
|
| Mexico | 4 | 2017 | 68 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 1992 | 54 | 0.110 |
Why?
|
| Leucine | 2 | 2003 | 67 | 0.110 |
Why?
|
| Age Factors | 6 | 2000 | 1848 | 0.110 |
Why?
|
| Family Health | 4 | 2017 | 162 | 0.110 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2012 | 74 | 0.110 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 1992 | 18 | 0.100 |
Why?
|
| Oxidative Stress | 1 | 2015 | 453 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2014 | 284 | 0.100 |
Why?
|
| Finland | 3 | 2017 | 28 | 0.100 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2012 | 49 | 0.100 |
Why?
|
| Bone and Bones | 1 | 2013 | 265 | 0.100 |
Why?
|
| Central Nervous System | 2 | 2007 | 152 | 0.100 |
Why?
|
| Selection, Genetic | 3 | 2009 | 505 | 0.100 |
Why?
|
| Chromosome Banding | 5 | 1995 | 74 | 0.100 |
Why?
|
| Polymorphism, Restriction Fragment Length | 3 | 1997 | 147 | 0.100 |
Why?
|
| Muscle Fibers, Skeletal | 2 | 2004 | 46 | 0.100 |
Why?
|
| Body Weight | 2 | 2011 | 451 | 0.100 |
Why?
|
| RNA Splicing | 1 | 1992 | 147 | 0.100 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 5 | 1997 | 28 | 0.100 |
Why?
|
| HLA-DQ Antigens | 1 | 2011 | 51 | 0.100 |
Why?
|
| Pseudomonas fluorescens | 2 | 2000 | 4 | 0.100 |
Why?
|
| Protein Tyrosine Phosphatases | 3 | 1996 | 46 | 0.090 |
Why?
|
| Risk Factors | 6 | 2019 | 5373 | 0.090 |
Why?
|
| Rodentia | 3 | 1995 | 42 | 0.090 |
Why?
|
| Up-Regulation | 4 | 2015 | 725 | 0.090 |
Why?
|
| Models, Theoretical | 1 | 2013 | 485 | 0.090 |
Why?
|
| Rats, Zucker | 5 | 1996 | 38 | 0.090 |
Why?
|
| Autoantibodies | 2 | 2011 | 267 | 0.090 |
Why?
|
| Karyotyping | 4 | 2000 | 253 | 0.090 |
Why?
|
| Sequence Deletion | 5 | 1997 | 206 | 0.090 |
Why?
|
| Hypertension | 1 | 2016 | 718 | 0.090 |
Why?
|
| Trisomy | 2 | 2000 | 55 | 0.090 |
Why?
|
| Hyperinsulinism | 1 | 2010 | 47 | 0.090 |
Why?
|
| Receptor, Insulin | 2 | 2017 | 54 | 0.090 |
Why?
|
| Organ Size | 2 | 2008 | 365 | 0.090 |
Why?
|
| Cell Differentiation | 4 | 2005 | 1501 | 0.090 |
Why?
|
| Mice, Knockout | 5 | 2019 | 1967 | 0.090 |
Why?
|
| TCF Transcription Factors | 1 | 2009 | 24 | 0.090 |
Why?
|
| Incretins | 1 | 2009 | 14 | 0.090 |
Why?
|
| Illinois | 1 | 2011 | 464 | 0.090 |
Why?
|
| Kinetics | 7 | 2006 | 1525 | 0.090 |
Why?
|
| Insulin Receptor Substrate Proteins | 3 | 2002 | 55 | 0.090 |
Why?
|
| Lod Score | 5 | 2004 | 152 | 0.090 |
Why?
|
| Smegmamorpha | 1 | 2009 | 3 | 0.090 |
Why?
|
| Recombinant Fusion Proteins | 5 | 2004 | 562 | 0.090 |
Why?
|
| Peromyscus | 1 | 2009 | 13 | 0.090 |
Why?
|
| Precision Medicine | 2 | 2013 | 406 | 0.090 |
Why?
|
| Trinidad and Tobago | 2 | 2011 | 4 | 0.090 |
Why?
|
| Cell Proliferation | 2 | 2013 | 1621 | 0.090 |
Why?
|
| Indians, North American | 3 | 2001 | 47 | 0.090 |
Why?
|
| Down-Regulation | 2 | 2015 | 512 | 0.090 |
Why?
|
| Spinal Cord Injuries | 2 | 2002 | 53 | 0.080 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 5 | 1996 | 17 | 0.080 |
Why?
|
| Blood Pressure | 3 | 2019 | 884 | 0.080 |
Why?
|
| Diet, Atherogenic | 1 | 2008 | 15 | 0.080 |
Why?
|
| Finches | 1 | 2009 | 56 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 3 | 2006 | 738 | 0.080 |
Why?
|
| Glutamate Decarboxylase | 3 | 2011 | 32 | 0.080 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 2007 | 13 | 0.080 |
Why?
|
| Amyloid | 2 | 2000 | 85 | 0.080 |
Why?
|
| Lipids | 1 | 2009 | 269 | 0.080 |
Why?
|
| Heterochromatin | 1 | 2007 | 22 | 0.080 |
Why?
|
| Sweetening Agents | 1 | 2007 | 17 | 0.080 |
Why?
|
| Genomics | 1 | 2013 | 737 | 0.080 |
Why?
|
| DNA, Satellite | 4 | 1995 | 19 | 0.080 |
Why?
|
| Chi-Square Distribution | 3 | 2011 | 360 | 0.080 |
Why?
|
| Insulinoma | 3 | 2002 | 37 | 0.080 |
Why?
|
| Cell Culture Techniques | 2 | 2005 | 188 | 0.080 |
Why?
|
| Blotting, Northern | 8 | 1997 | 259 | 0.080 |
Why?
|
| Sex Characteristics | 4 | 2018 | 320 | 0.080 |
Why?
|
| Cohort Studies | 4 | 2015 | 2791 | 0.080 |
Why?
|
| Prevalence | 2 | 2011 | 1246 | 0.080 |
Why?
|
| Lymphocytes | 3 | 1994 | 469 | 0.080 |
Why?
|
| Birth Weight | 1 | 2007 | 145 | 0.070 |
Why?
|
| Galactose | 2 | 1997 | 32 | 0.070 |
Why?
|
| X Chromosome | 1 | 2007 | 152 | 0.070 |
Why?
|
| Receptors, Leptin | 2 | 1997 | 32 | 0.070 |
Why?
|
| Protein Structure, Secondary | 3 | 2006 | 330 | 0.070 |
Why?
|
| Zinc Fingers | 2 | 2005 | 57 | 0.070 |
Why?
|
| Peptides, Cyclic | 4 | 1995 | 43 | 0.070 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 3 | 1997 | 269 | 0.070 |
Why?
|
| Transcriptome | 3 | 2019 | 609 | 0.070 |
Why?
|
| Africa | 2 | 2004 | 101 | 0.070 |
Why?
|
| Gene Expression Profiling | 3 | 2013 | 1412 | 0.070 |
Why?
|
| Abdominal Fat | 1 | 2006 | 13 | 0.070 |
Why?
|
| Models, Biological | 7 | 2010 | 1759 | 0.070 |
Why?
|
| Apolipoproteins | 1 | 2006 | 37 | 0.070 |
Why?
|
| Cysteine Proteinase Inhibitors | 2 | 2003 | 53 | 0.070 |
Why?
|
| Disease Models, Animal | 4 | 2014 | 2300 | 0.070 |
Why?
|
| Phosphoprotein Phosphatases | 2 | 2004 | 58 | 0.070 |
Why?
|
| Mutant Proteins | 1 | 2006 | 94 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 6 | 2010 | 3161 | 0.070 |
Why?
|
| Time Factors | 6 | 2004 | 5262 | 0.070 |
Why?
|
| Pyrrolidines | 3 | 1994 | 59 | 0.070 |
Why?
|
| Upstream Stimulatory Factors | 1 | 2005 | 5 | 0.070 |
Why?
|
| Codon | 5 | 1997 | 123 | 0.070 |
Why?
|
| Sex-Determining Region Y Protein | 1 | 2005 | 3 | 0.070 |
Why?
|
| Colforsin | 6 | 1994 | 74 | 0.070 |
Why?
|
| Decision Making | 1 | 2011 | 651 | 0.070 |
Why?
|
| Aminoimidazole Carboxamide | 1 | 2005 | 7 | 0.070 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2005 | 55 | 0.070 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 1996 | 137 | 0.070 |
Why?
|
| Aging | 2 | 2002 | 696 | 0.070 |
Why?
|
| RNA, Ribosomal | 1 | 2005 | 60 | 0.070 |
Why?
|
| Transcriptional Activation | 2 | 2004 | 286 | 0.060 |
Why?
|
| Ribonucleosides | 1 | 2005 | 25 | 0.060 |
Why?
|
| Multienzyme Complexes | 1 | 2005 | 65 | 0.060 |
Why?
|
| Abnormalities, Multiple | 2 | 2000 | 233 | 0.060 |
Why?
|
| In Vitro Techniques | 7 | 2005 | 993 | 0.060 |
Why?
|
| Nuclear Respiratory Factors | 1 | 2004 | 1 | 0.060 |
Why?
|
| NF-E2-Related Factor 1 | 1 | 2004 | 1 | 0.060 |
Why?
|
| Myogenin | 1 | 2004 | 5 | 0.060 |
Why?
|
| Nuclear Respiratory Factor 1 | 1 | 2004 | 6 | 0.060 |
Why?
|
| United States | 6 | 2014 | 6769 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 4 | 2 | 1996 | 48 | 0.060 |
Why?
|
| MyoD Protein | 1 | 2004 | 15 | 0.060 |
Why?
|
| Transcription Initiation Site | 1 | 2004 | 45 | 0.060 |
Why?
|
| Primidone | 1 | 2004 | 2 | 0.060 |
Why?
|
| Crosses, Genetic | 2 | 2013 | 171 | 0.060 |
Why?
|
| Analgesics | 3 | 1994 | 119 | 0.060 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2004 | 73 | 0.060 |
Why?
|
| Triglycerides | 2 | 2003 | 231 | 0.060 |
Why?
|
| Benzeneacetamides | 2 | 1994 | 11 | 0.060 |
Why?
|
| Phenobarbital | 1 | 2004 | 33 | 0.060 |
Why?
|
| NIH 3T3 Cells | 1 | 2004 | 108 | 0.060 |
Why?
|
| Epidermal Growth Factor | 2 | 1996 | 117 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 5 | 2002 | 1048 | 0.060 |
Why?
|
| Homeostasis | 2 | 2006 | 406 | 0.060 |
Why?
|
| Drug Combinations | 1 | 2004 | 201 | 0.060 |
Why?
|
| CpG Islands | 1 | 2004 | 155 | 0.060 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 2004 | 25 | 0.060 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 2 | 2015 | 33 | 0.060 |
Why?
|
| Cholesterol, HDL | 2 | 2003 | 164 | 0.060 |
Why?
|
| United Kingdom | 5 | 2004 | 162 | 0.060 |
Why?
|
| Myocardium | 4 | 1995 | 560 | 0.060 |
Why?
|
| Drug Utilization | 1 | 2004 | 65 | 0.060 |
Why?
|
| Fluorescence | 2 | 1995 | 102 | 0.060 |
Why?
|
| Hyperlipidemia, Familial Combined | 1 | 2003 | 5 | 0.060 |
Why?
|
| Xenopus laevis | 2 | 1995 | 137 | 0.060 |
Why?
|
| Cell Line, Tumor | 1 | 2009 | 2500 | 0.060 |
Why?
|
| Xenopus | 5 | 1996 | 125 | 0.060 |
Why?
|
| Ginsenosides | 1 | 2004 | 123 | 0.060 |
Why?
|
| India | 1 | 2004 | 121 | 0.060 |
Why?
|
| Islet Amyloid Polypeptide | 3 | 2017 | 25 | 0.060 |
Why?
|
| Betacellulin | 1 | 2003 | 3 | 0.060 |
Why?
|
| Founder Effect | 1 | 2004 | 104 | 0.060 |
Why?
|
| Fructose | 2 | 1994 | 35 | 0.060 |
Why?
|
| Anticonvulsants | 1 | 2004 | 126 | 0.060 |
Why?
|
| Bacterial Typing Techniques | 2 | 2000 | 28 | 0.060 |
Why?
|
| Glutamic Acid | 1 | 2004 | 154 | 0.060 |
Why?
|
| Cholesterol | 2 | 2003 | 354 | 0.060 |
Why?
|
| Animals, Genetically Modified | 2 | 2013 | 182 | 0.060 |
Why?
|
| Genes, Reporter | 3 | 2013 | 272 | 0.060 |
Why?
|
| Mosaicism | 2 | 2000 | 70 | 0.060 |
Why?
|
| Diabetic Nephropathies | 1 | 2003 | 87 | 0.060 |
Why?
|
| Eye | 2 | 2013 | 111 | 0.060 |
Why?
|
| Lysine | 1 | 2004 | 149 | 0.060 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2003 | 18 | 0.060 |
Why?
|
| Gene Knockdown Techniques | 2 | 2014 | 241 | 0.060 |
Why?
|
| China | 3 | 2005 | 230 | 0.050 |
Why?
|
| Gene Deletion | 2 | 2001 | 340 | 0.050 |
Why?
|
| RNA Interference | 2 | 2014 | 372 | 0.050 |
Why?
|
| Cell Nucleus | 2 | 2002 | 588 | 0.050 |
Why?
|
| Terminology as Topic | 2 | 2002 | 219 | 0.050 |
Why?
|
| Nuclear Family | 3 | 1997 | 91 | 0.050 |
Why?
|
| Signal Transduction | 8 | 1997 | 3327 | 0.050 |
Why?
|
| Pain, Postoperative | 1 | 2004 | 246 | 0.050 |
Why?
|
| Quantitative Trait, Heritable | 3 | 2013 | 124 | 0.050 |
Why?
|
| Heart Rate | 1 | 2004 | 488 | 0.050 |
Why?
|
| Chromosomes, Artificial, Bacterial | 2 | 2012 | 30 | 0.050 |
Why?
|
| 3T3 Cells | 4 | 1996 | 96 | 0.050 |
Why?
|
| Streptozocin | 2 | 2013 | 55 | 0.050 |
Why?
|
| Adenoviridae | 1 | 2003 | 347 | 0.050 |
Why?
|
| Glucose Transporter Type 4 | 4 | 2007 | 17 | 0.050 |
Why?
|
| Electric Stimulation Therapy | 1 | 2002 | 44 | 0.050 |
Why?
|
| Genes, Dominant | 4 | 2012 | 117 | 0.050 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 6612 | 0.050 |
Why?
|
| Protein Isoforms | 2 | 2017 | 273 | 0.050 |
Why?
|
| Structure-Activity Relationship | 4 | 1994 | 409 | 0.050 |
Why?
|
| Inheritance Patterns | 1 | 2021 | 48 | 0.050 |
Why?
|
| Yolk Sac | 1 | 2001 | 4 | 0.050 |
Why?
|
| State Medicine | 1 | 2000 | 12 | 0.050 |
Why?
|
| Genomic Imprinting | 1 | 2001 | 33 | 0.050 |
Why?
|
| Untranslated Regions | 1 | 2000 | 18 | 0.050 |
Why?
|
| Glucagon | 2 | 2017 | 112 | 0.050 |
Why?
|
| Germany | 2 | 1997 | 72 | 0.050 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2021 | 85 | 0.050 |
Why?
|
| Mutagenesis, Site-Directed | 4 | 1994 | 282 | 0.050 |
Why?
|
| Contact Tracing | 2 | 2000 | 29 | 0.050 |
Why?
|
| Pancreatic Polypeptide | 1 | 2000 | 9 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2002 | 686 | 0.050 |
Why?
|
| Patient Satisfaction | 2 | 2000 | 456 | 0.050 |
Why?
|
| Base Pair Mismatch | 1 | 2000 | 27 | 0.050 |
Why?
|
| HSC70 Heat-Shock Proteins | 1 | 2000 | 5 | 0.050 |
Why?
|
| History, 21st Century | 1 | 2021 | 176 | 0.050 |
Why?
|
| Sepharose | 1 | 2000 | 14 | 0.050 |
Why?
|
| Fetus | 3 | 2000 | 230 | 0.050 |
Why?
|
| Ecosystem | 2 | 2000 | 324 | 0.050 |
Why?
|
| Hepatocyte Nuclear Factor 3-beta | 1 | 2000 | 5 | 0.050 |
Why?
|
| Neuropeptides | 1 | 2000 | 113 | 0.050 |
Why?
|
| Nephrons | 1 | 2000 | 18 | 0.050 |
Why?
|
| Chromatography, Affinity | 1 | 2000 | 81 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2002 | 383 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2000 | 42 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2000 | 54 | 0.050 |
Why?
|
| Leptin | 2 | 1997 | 104 | 0.050 |
Why?
|
| Developmental Disabilities | 2 | 2013 | 201 | 0.040 |
Why?
|
| Patch-Clamp Techniques | 3 | 1996 | 397 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 3 | 1997 | 1223 | 0.040 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2000 | 46 | 0.040 |
Why?
|
| Young Adult | 3 | 2019 | 6116 | 0.040 |
Why?
|
| Fetal Diseases | 1 | 2000 | 82 | 0.040 |
Why?
|
| Neuropeptide Y | 2 | 1996 | 31 | 0.040 |
Why?
|
| Tooth Abnormalities | 2 | 1996 | 6 | 0.040 |
Why?
|
| Prenatal Diagnosis | 1 | 2000 | 110 | 0.040 |
Why?
|
| DNA Transposable Elements | 1 | 2000 | 170 | 0.040 |
Why?
|
| Mitochondria | 1 | 2003 | 542 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 1674 | 0.040 |
Why?
|
| New South Wales | 1 | 2019 | 3 | 0.040 |
Why?
|
| Drug Synergism | 2 | 2013 | 303 | 0.040 |
Why?
|
| Serogroup | 1 | 2019 | 9 | 0.040 |
Why?
|
| Water Quality | 1 | 2018 | 2 | 0.040 |
Why?
|
| Animals, Domestic | 1 | 2019 | 12 | 0.040 |
Why?
|
| Drosophila melanogaster | 2 | 2013 | 599 | 0.040 |
Why?
|
| Environmental Microbiology | 1 | 2019 | 22 | 0.040 |
Why?
|
| Groundwater | 1 | 2018 | 10 | 0.040 |
Why?
|
| Animals, Wild | 1 | 2019 | 41 | 0.040 |
Why?
|
| Water Supply | 1 | 2018 | 60 | 0.040 |
Why?
|
| Adaptation, Physiological | 2 | 2000 | 313 | 0.040 |
Why?
|
| Cancer Vaccines | 1 | 2000 | 159 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2009 | 2260 | 0.040 |
Why?
|
| Phosphatidylethanolamine N-Methyltransferase | 1 | 2018 | 1 | 0.040 |
Why?
|
| Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide | 2 | 1995 | 2 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 1996 | 216 | 0.040 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2018 | 12 | 0.040 |
Why?
|
| Disease Transmission, Infectious | 1 | 2019 | 58 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2017 | 682 | 0.040 |
Why?
|
| Coronary Artery Disease | 1 | 2003 | 357 | 0.040 |
Why?
|
| Substrate Specificity | 3 | 1993 | 350 | 0.040 |
Why?
|
| Sodium | 3 | 1993 | 331 | 0.040 |
Why?
|
| Rural Population | 1 | 2018 | 140 | 0.040 |
Why?
|
| Microscopy, Fluorescence | 3 | 2005 | 427 | 0.040 |
Why?
|
| Bangladesh | 1 | 2018 | 319 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2000 | 330 | 0.040 |
Why?
|
| Glycine | 2 | 1995 | 93 | 0.040 |
Why?
|
| Rats, Mutant Strains | 1 | 1997 | 23 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2000 | 336 | 0.040 |
Why?
|
| Cell Compartmentation | 2 | 1994 | 69 | 0.040 |
Why?
|
| Tropomyosin | 1 | 1997 | 16 | 0.040 |
Why?
|
| Diploidy | 1 | 1997 | 31 | 0.040 |
Why?
|
| Phosphorylation | 2 | 1997 | 1121 | 0.040 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 164 | 0.040 |
Why?
|
| Haploidy | 1 | 1997 | 32 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2000 | 352 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2000 | 1073 | 0.040 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 1997 | 9 | 0.040 |
Why?
|
| Genes, Fungal | 1 | 1997 | 58 | 0.040 |
Why?
|
| Directed Molecular Evolution | 1 | 1997 | 20 | 0.040 |
Why?
|
| Cell Membrane | 3 | 1995 | 667 | 0.040 |
Why?
|
| Receptors, Chemokine | 1 | 1997 | 31 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2017 | 81 | 0.040 |
Why?
|
| Octreotide | 2 | 1995 | 16 | 0.040 |
Why?
|
| Molecular Probes | 2 | 1996 | 35 | 0.040 |
Why?
|
| Multifactorial Inheritance | 1 | 2019 | 164 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2015 | 595 | 0.040 |
Why?
|
| Chemokines, CC | 1 | 1997 | 36 | 0.040 |
Why?
|
| Catecholamines | 1 | 1997 | 91 | 0.040 |
Why?
|
| Intracellular Membranes | 4 | 2001 | 117 | 0.040 |
Why?
|
| Membrane Potentials | 2 | 1996 | 436 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2000 | 343 | 0.040 |
Why?
|
| Family | 4 | 2004 | 316 | 0.040 |
Why?
|
| Fructose Intolerance | 1 | 1996 | 2 | 0.040 |
Why?
|
| Time | 1 | 1997 | 77 | 0.040 |
Why?
|
| Umbilicus | 1 | 1996 | 5 | 0.040 |
Why?
|
| ras Proteins | 1 | 2018 | 130 | 0.040 |
Why?
|
| Dimerization | 1 | 1997 | 143 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2000 | 409 | 0.040 |
Why?
|
| Chemokines | 1 | 1997 | 74 | 0.040 |
Why?
|
| Placenta | 2 | 2000 | 178 | 0.040 |
Why?
|
| Aspartic Acid | 2 | 1993 | 64 | 0.040 |
Why?
|
| Craniofacial Abnormalities | 1 | 1996 | 36 | 0.040 |
Why?
|
| Arcuate Nucleus of Hypothalamus | 1 | 1996 | 16 | 0.040 |
Why?
|
| Receptors, Endothelin | 1 | 1996 | 12 | 0.040 |
Why?
|
| Enzyme Activation | 3 | 2005 | 694 | 0.040 |
Why?
|
| Molecular Weight | 2 | 1994 | 332 | 0.040 |
Why?
|
| Pseudogenes | 2 | 1995 | 34 | 0.040 |
Why?
|
| Pulse Wave Analysis | 1 | 2016 | 10 | 0.040 |
Why?
|
| Sequence Tagged Sites | 1 | 1996 | 11 | 0.040 |
Why?
|
| DNA, Recombinant | 1 | 1996 | 67 | 0.040 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1996 | 49 | 0.040 |
Why?
|
| Glaucoma | 1 | 1996 | 31 | 0.030 |
Why?
|
| Transferases | 1 | 1996 | 23 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2016 | 11 | 0.030 |
Why?
|
| tRNA Methyltransferases | 1 | 2016 | 14 | 0.030 |
Why?
|
| KCNQ1 Potassium Channel | 1 | 2016 | 16 | 0.030 |
Why?
|
| Vascular Stiffness | 1 | 2016 | 29 | 0.030 |
Why?
|
| Nitric Oxide Synthase | 1 | 1996 | 125 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 68 | 0.030 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2015 | 18 | 0.030 |
Why?
|
| Sample Size | 1 | 2016 | 129 | 0.030 |
Why?
|
| Cytoprotection | 1 | 2016 | 47 | 0.030 |
Why?
|
| Blotting, Southern | 2 | 1992 | 129 | 0.030 |
Why?
|
| Regulatory Elements, Transcriptional | 1 | 2016 | 45 | 0.030 |
Why?
|
| Translocation, Genetic | 1 | 1996 | 266 | 0.030 |
Why?
|
| Plasmids | 1 | 1996 | 292 | 0.030 |
Why?
|
| Fetal Growth Retardation | 1 | 1996 | 67 | 0.030 |
Why?
|
| Oxidoreductases | 1 | 1996 | 112 | 0.030 |
Why?
|
| DNA, Single-Stranded | 2 | 1993 | 91 | 0.030 |
Why?
|
| Fructose-1,6-Diphosphatase Deficiency | 1 | 1995 | 1 | 0.030 |
Why?
|
| Fructose-Bisphosphatase | 1 | 1995 | 3 | 0.030 |
Why?
|
| Europe | 1 | 2016 | 312 | 0.030 |
Why?
|
| Primates | 1 | 1997 | 155 | 0.030 |
Why?
|
| Receptors, Glucocorticoid | 1 | 1996 | 129 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 108 | 0.030 |
Why?
|
| Endocrine Glands | 1 | 1995 | 13 | 0.030 |
Why?
|
| RNA, Transfer, Leu | 1 | 1995 | 11 | 0.030 |
Why?
|
| Genetic Diseases, Inborn | 1 | 1996 | 101 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2007 | 8712 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 994 | 0.030 |
Why?
|
| Amino Acid Transport Systems, Neutral | 1 | 1995 | 5 | 0.030 |
Why?
|
| Glycemic Index | 1 | 2015 | 10 | 0.030 |
Why?
|
| Growth Inhibitors | 1 | 1995 | 41 | 0.030 |
Why?
|
| Feedback | 1 | 1995 | 134 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1997 | 297 | 0.030 |
Why?
|
| Synaptic Transmission | 1 | 1996 | 224 | 0.030 |
Why?
|
| LIM-Homeodomain Proteins | 1 | 1994 | 21 | 0.030 |
Why?
|
| Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I | 1 | 1994 | 2 | 0.030 |
Why?
|
| Biological Transport | 2 | 1992 | 399 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 1996 | 278 | 0.030 |
Why?
|
| Chickens | 1 | 1995 | 212 | 0.030 |
Why?
|
| Stem Cells | 1 | 2017 | 364 | 0.030 |
Why?
|
| Ischemic Attack, Transient | 1 | 1996 | 181 | 0.030 |
Why?
|
| Diabetes, Gestational | 1 | 1995 | 40 | 0.030 |
Why?
|
| Dynorphins | 1 | 1994 | 14 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2015 | 190 | 0.030 |
Why?
|
| Radioligand Assay | 4 | 1996 | 32 | 0.030 |
Why?
|
| Hong Kong | 2 | 2004 | 45 | 0.030 |
Why?
|
| Naloxone | 1 | 1994 | 63 | 0.030 |
Why?
|
| Bcl-2-Like Protein 11 | 1 | 2014 | 23 | 0.030 |
Why?
|
| Lentivirus | 1 | 2014 | 36 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 1996 | 431 | 0.030 |
Why?
|
| Sulfotransferases | 1 | 2013 | 19 | 0.030 |
Why?
|
| Blindness, Cortical | 1 | 2013 | 8 | 0.030 |
Why?
|
| Neurologic Manifestations | 1 | 2013 | 11 | 0.030 |
Why?
|
| Heparitin Sulfate | 1 | 2013 | 27 | 0.030 |
Why?
|
| Spinal Cord | 1 | 1995 | 249 | 0.030 |
Why?
|
| Receptors, Opioid, mu | 1 | 1994 | 45 | 0.030 |
Why?
|
| Intestine, Small | 2 | 1994 | 303 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2013 | 1818 | 0.030 |
Why?
|
| Phosphorylases | 1 | 1993 | 4 | 0.030 |
Why?
|
| Proprotein Convertase 2 | 1 | 1993 | 11 | 0.030 |
Why?
|
| Syndrome | 2 | 2010 | 446 | 0.030 |
Why?
|
| Thrombomodulin | 1 | 1993 | 7 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2016 | 506 | 0.030 |
Why?
|
| Exocytosis | 2 | 2009 | 108 | 0.030 |
Why?
|
| Glyburide | 2 | 2008 | 31 | 0.030 |
Why?
|
| Virulence Factors, Bordetella | 4 | 1994 | 26 | 0.030 |
Why?
|
| Pertussis Toxin | 4 | 1994 | 31 | 0.030 |
Why?
|
| Subtilisins | 1 | 1993 | 27 | 0.030 |
Why?
|
| Urogenital System | 1 | 2013 | 9 | 0.030 |
Why?
|
| RNA-Binding Proteins | 1 | 2016 | 255 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2013 | 43 | 0.030 |
Why?
|
| Osmolar Concentration | 3 | 2001 | 181 | 0.030 |
Why?
|
| Amino Acids | 1 | 1994 | 251 | 0.030 |
Why?
|
| Longitudinal Studies | 2 | 2011 | 1031 | 0.030 |
Why?
|
| Weaning | 1 | 2013 | 25 | 0.030 |
Why?
|
| Cerebellum | 1 | 1995 | 249 | 0.030 |
Why?
|
| Thyroxine-Binding Proteins | 1 | 1993 | 86 | 0.030 |
Why?
|
| Threonine | 1 | 1993 | 34 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 1996 | 323 | 0.030 |
Why?
|
| Collagen Type I | 1 | 2013 | 64 | 0.030 |
Why?
|
| Epistasis, Genetic | 1 | 2013 | 89 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2013 | 231 | 0.030 |
Why?
|
| Movement | 1 | 1995 | 301 | 0.030 |
Why?
|
| Wings, Animal | 1 | 2013 | 96 | 0.030 |
Why?
|
| Cytochalasin B | 1 | 1992 | 19 | 0.030 |
Why?
|
| RNA Probes | 1 | 1992 | 16 | 0.030 |
Why?
|
| Pepsinogens | 1 | 1992 | 1 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 1993 | 229 | 0.030 |
Why?
|
| Alanine | 1 | 1993 | 85 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2013 | 208 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2013 | 295 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2013 | 136 | 0.030 |
Why?
|
| Superior Colliculi | 1 | 1992 | 21 | 0.030 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 1992 | 15 | 0.030 |
Why?
|
| Genes, Wilms Tumor | 1 | 1992 | 6 | 0.030 |
Why?
|
| Spleen | 1 | 1994 | 430 | 0.030 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1992 | 68 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2013 | 369 | 0.030 |
Why?
|
| Receptors, Neurotransmitter | 1 | 1992 | 26 | 0.030 |
Why?
|
| Cytosol | 1 | 1993 | 190 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2015 | 273 | 0.030 |
Why?
|
| NADP | 2 | 2003 | 45 | 0.030 |
Why?
|
| Receptors, Dopamine D1 | 1 | 1992 | 33 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 2 | 1995 | 656 | 0.030 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1992 | 245 | 0.030 |
Why?
|
| Cerebral Cortex | 2 | 1996 | 586 | 0.030 |
Why?
|
| Mesencephalon | 1 | 1992 | 64 | 0.030 |
Why?
|
| Spermatozoa | 1 | 1992 | 62 | 0.030 |
Why?
|
| Databases, Factual | 1 | 1996 | 837 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 554 | 0.030 |
Why?
|
| Sirolimus | 1 | 2013 | 171 | 0.030 |
Why?
|
| Receptors, Thyroid Hormone | 1 | 1992 | 159 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2004 | 696 | 0.030 |
Why?
|
| Tacrolimus | 1 | 2013 | 373 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 1994 | 737 | 0.030 |
Why?
|
| Gene Order | 1 | 2011 | 22 | 0.030 |
Why?
|
| HLA-DQ alpha-Chains | 1 | 2011 | 16 | 0.020 |
Why?
|
| Mammals | 1 | 1993 | 232 | 0.020 |
Why?
|
| COS Cells | 2 | 2002 | 167 | 0.020 |
Why?
|
| Glucose Transporter Type 5 | 3 | 1996 | 6 | 0.020 |
Why?
|
| Chicago | 2 | 2011 | 1394 | 0.020 |
Why?
|
| England | 2 | 2003 | 41 | 0.020 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2011 | 80 | 0.020 |
Why?
|
| 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer | 3 | 1994 | 10 | 0.020 |
Why?
|
| Species Specificity | 1 | 2012 | 682 | 0.020 |
Why?
|
| Congenital Hyperinsulinism | 1 | 2010 | 13 | 0.020 |
Why?
|
| Cognition | 1 | 1995 | 576 | 0.020 |
Why?
|
| Genetic Complementation Test | 1 | 2010 | 97 | 0.020 |
Why?
|
| Pancreatic Diseases | 1 | 2010 | 52 | 0.020 |
Why?
|
| Histocytochemistry | 3 | 1994 | 130 | 0.020 |
Why?
|
| Gene Knockout Techniques | 1 | 2010 | 79 | 0.020 |
Why?
|
| Molecular Biology | 1 | 2010 | 89 | 0.020 |
Why?
|
| Health Services Research | 2 | 2000 | 136 | 0.020 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2009 | 30 | 0.020 |
Why?
|
| Perilipin-1 | 1 | 2009 | 7 | 0.020 |
Why?
|
| eIF-2 Kinase | 1 | 2010 | 46 | 0.020 |
Why?
|
| Lung | 1 | 1996 | 1226 | 0.020 |
Why?
|
| Rats, Wistar | 3 | 1996 | 300 | 0.020 |
Why?
|
| Cell Division | 3 | 1997 | 695 | 0.020 |
Why?
|
| Models, Molecular | 1 | 1994 | 1290 | 0.020 |
Why?
|
| Sex Factors | 3 | 2000 | 1055 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2013 | 1535 | 0.020 |
Why?
|
| Glucose Clamp Technique | 1 | 2009 | 39 | 0.020 |
Why?
|
| Body Composition | 1 | 2009 | 69 | 0.020 |
Why?
|
| Hybridization, Genetic | 1 | 2010 | 106 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 2004 | 901 | 0.020 |
Why?
|
| Haplorhini | 2 | 2002 | 81 | 0.020 |
Why?
|
| Gestational Age | 2 | 2000 | 315 | 0.020 |
Why?
|
| Drosophila Proteins | 1 | 2013 | 492 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2010 | 169 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2012 | 492 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2009 | 518 | 0.020 |
Why?
|
| Norway | 1 | 2008 | 8 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2013 | 984 | 0.020 |
Why?
|
| Arginine | 2 | 2000 | 137 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2008 | 172 | 0.020 |
Why?
|
| Protein Precursors | 1 | 2007 | 143 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 1992 | 1232 | 0.020 |
Why?
|
| Macaca fascicularis | 2 | 1996 | 107 | 0.020 |
Why?
|
| Enzyme Stability | 1 | 2006 | 39 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2004 | 1936 | 0.020 |
Why?
|
| Peptides | 2 | 2004 | 644 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2009 | 942 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2006 | 50 | 0.020 |
Why?
|
| Biomarkers | 1 | 2012 | 1733 | 0.020 |
Why?
|
| Tolbutamide | 2 | 1997 | 16 | 0.020 |
Why?
|
| Autoradiography | 2 | 1996 | 69 | 0.020 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2005 | 27 | 0.020 |
Why?
|
| Disease Progression | 1 | 2009 | 1473 | 0.020 |
Why?
|
| Carbachol | 2 | 1995 | 36 | 0.020 |
Why?
|
| 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 2 | 1996 | 13 | 0.020 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2005 | 64 | 0.020 |
Why?
|
| Hospitalization | 2 | 2000 | 858 | 0.020 |
Why?
|
| Cattle | 2 | 1996 | 376 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2006 | 484 | 0.020 |
Why?
|
| Oligonucleotide Probes | 2 | 1994 | 39 | 0.020 |
Why?
|
| AT Rich Sequence | 1 | 2004 | 7 | 0.020 |
Why?
|
| Risk | 1 | 2006 | 660 | 0.020 |
Why?
|
| Electrophysiology | 2 | 1996 | 402 | 0.020 |
Why?
|
| Ryanodine | 1 | 2004 | 4 | 0.020 |
Why?
|
| Dantrolene | 1 | 2004 | 5 | 0.020 |
Why?
|
| Glucagon-Like Peptides | 1 | 2004 | 5 | 0.020 |
Why?
|
| Palmitic Acids | 1 | 2004 | 8 | 0.020 |
Why?
|
| Chromosome Segregation | 1 | 2004 | 32 | 0.020 |
Why?
|
| PC12 Cells | 2 | 1994 | 115 | 0.020 |
Why?
|
| Protein Subunits | 1 | 2004 | 123 | 0.020 |
Why?
|
| Gluconeogenesis | 1 | 2004 | 14 | 0.020 |
Why?
|
| Protein Phosphatase 1 | 1 | 2004 | 34 | 0.020 |
Why?
|
| Carbohydrate Metabolism | 1 | 2004 | 29 | 0.020 |
Why?
|
| Precipitin Tests | 1 | 2004 | 110 | 0.010 |
Why?
|
| Serotyping | 1 | 2003 | 28 | 0.010 |
Why?
|
| RNA Polymerase II | 1 | 2004 | 56 | 0.010 |
Why?
|
| Incidence | 2 | 2000 | 1569 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2004 | 160 | 0.010 |
Why?
|
| Guanosine Triphosphate | 2 | 1993 | 38 | 0.010 |
Why?
|
| Caspases | 1 | 2004 | 155 | 0.010 |
Why?
|
| Albuminuria | 1 | 2003 | 48 | 0.010 |
Why?
|
| Registries | 1 | 2008 | 733 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2005 | 299 | 0.010 |
Why?
|
| Binding, Competitive | 2 | 1993 | 146 | 0.010 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2003 | 54 | 0.010 |
Why?
|
| Cricetulus | 2 | 1993 | 126 | 0.010 |
Why?
|
| Hyperlipoproteinemias | 1 | 2003 | 7 | 0.010 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 2 | 1993 | 11 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2004 | 271 | 0.010 |
Why?
|
| Dipeptides | 1 | 2003 | 42 | 0.010 |
Why?
|
| Testis | 2 | 1995 | 152 | 0.010 |
Why?
|
| Antigens, Bacterial | 1 | 2003 | 135 | 0.010 |
Why?
|
| Scandinavian and Nordic Countries | 1 | 2002 | 8 | 0.010 |
Why?
|
| Adenylate Cyclase Toxin | 2 | 1993 | 14 | 0.010 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 2 | 1993 | 29 | 0.010 |
Why?
|
| Control Groups | 1 | 2002 | 15 | 0.010 |
Why?
|
| DNA, Bacterial | 1 | 2003 | 237 | 0.010 |
Why?
|
| Cell Separation | 1 | 2003 | 195 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 2004 | 198 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2002 | 4232 | 0.010 |
Why?
|
| Prognosis | 1 | 2010 | 3708 | 0.010 |
Why?
|
| Seasons | 1 | 2003 | 226 | 0.010 |
Why?
|
| Receptor, Muscarinic M3 | 1 | 2002 | 12 | 0.010 |
Why?
|
| Quadriplegia | 1 | 2002 | 22 | 0.010 |
Why?
|
| Paraplegia | 1 | 2002 | 17 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 2002 | 72 | 0.010 |
Why?
|
| Ireland | 1 | 2002 | 9 | 0.010 |
Why?
|
| Protein Biosynthesis | 2 | 1994 | 387 | 0.010 |
Why?
|
| Body Constitution | 1 | 2002 | 26 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2003 | 376 | 0.010 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2002 | 77 | 0.010 |
Why?
|
| Electric Conductivity | 1 | 2001 | 144 | 0.010 |
Why?
|
| Cell Survival | 1 | 2004 | 977 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2002 | 353 | 0.010 |
Why?
|
| London | 1 | 2000 | 16 | 0.010 |
Why?
|
| Probability | 1 | 2002 | 356 | 0.010 |
Why?
|
| Arizona | 1 | 2000 | 10 | 0.010 |
Why?
|
| Dogs | 1 | 2002 | 698 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 2000 | 59 | 0.010 |
Why?
|
| RNA, Untranslated | 1 | 2001 | 63 | 0.010 |
Why?
|
| Chorionic Villi Sampling | 1 | 2000 | 13 | 0.010 |
Why?
|
| Genetics, Population | 1 | 2003 | 401 | 0.010 |
Why?
|
| Hernia, Diaphragmatic | 1 | 2000 | 10 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2002 | 678 | 0.010 |
Why?
|
| Interphase | 1 | 2000 | 35 | 0.010 |
Why?
|
| Patient Admission | 1 | 2000 | 113 | 0.010 |
Why?
|
| Oligopeptides | 1 | 2001 | 186 | 0.010 |
Why?
|
| Adipocytes | 1 | 2001 | 155 | 0.010 |
Why?
|
| Polycystic Kidney Diseases | 1 | 2000 | 20 | 0.010 |
Why?
|
| Fathers | 1 | 2001 | 70 | 0.010 |
Why?
|
| Genes, Bacterial | 1 | 2000 | 198 | 0.010 |
Why?
|
| Health Services Needs and Demand | 1 | 2000 | 103 | 0.010 |
Why?
|
| Mothers | 1 | 2001 | 143 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2004 | 1088 | 0.010 |
Why?
|
| RNA, Long Noncoding | 1 | 2001 | 112 | 0.010 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2000 | 153 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2000 | 280 | 0.010 |
Why?
|
| Receptors, CCR6 | 1 | 1997 | 3 | 0.010 |
Why?
|
| Chemokine CCL20 | 1 | 1997 | 3 | 0.010 |
Why?
|
| Biometry | 1 | 1997 | 66 | 0.010 |
Why?
|
| Denmark | 1 | 1997 | 16 | 0.010 |
Why?
|
| Abortion, Induced | 1 | 2000 | 123 | 0.010 |
Why?
|
| Muscle Fibers, Fast-Twitch | 1 | 1997 | 4 | 0.010 |
Why?
|
| Muscle Fibers, Slow-Twitch | 1 | 1997 | 4 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 1997 | 10 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 2015 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 2000 | 316 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2003 | 2733 | 0.010 |
Why?
|
| Chemotaxis | 1 | 1997 | 73 | 0.010 |
Why?
|
| Forms and Records Control | 1 | 1996 | 16 | 0.010 |
Why?
|
| Guanylate Cyclase | 1 | 1996 | 19 | 0.010 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 1996 | 31 | 0.010 |
Why?
|
| Glucose Transporter Type 1 | 1 | 1996 | 20 | 0.010 |
Why?
|
| Receptor, Endothelin B | 1 | 1996 | 5 | 0.010 |
Why?
|
| Myosin Heavy Chains | 1 | 1997 | 92 | 0.010 |
Why?
|
| Biopsy | 1 | 2000 | 1173 | 0.010 |
Why?
|
| Diabetic Angiopathies | 1 | 1996 | 37 | 0.010 |
Why?
|
| Communicable Disease Control | 1 | 1996 | 50 | 0.010 |
Why?
|
| Vasodilation | 1 | 1996 | 94 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2004 | 2556 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 1996 | 225 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 1996 | 48 | 0.010 |
Why?
|
| Adenosine Triphosphatases | 1 | 1997 | 154 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 1997 | 257 | 0.010 |
Why?
|
| Potassium Chloride | 1 | 1996 | 87 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1996 | 155 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1996 | 430 | 0.010 |
Why?
|
| Genes, ras | 1 | 1996 | 97 | 0.010 |
Why?
|
| Sexual Partners | 1 | 1996 | 97 | 0.010 |
Why?
|
| Cerebral Angiography | 1 | 1996 | 197 | 0.010 |
Why?
|
| Mice, Obese | 1 | 1995 | 43 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 1996 | 148 | 0.010 |
Why?
|
| Cholecystokinin | 1 | 1995 | 15 | 0.010 |
Why?
|
| Agouti Signaling Protein | 1 | 1995 | 2 | 0.010 |
Why?
|
| alpha-MSH | 1 | 1995 | 4 | 0.010 |
Why?
|
| Glucose Transporter Type 2 | 1 | 1995 | 10 | 0.010 |
Why?
|
| Hair Color | 1 | 1995 | 8 | 0.010 |
Why?
|
| Glycine Plasma Membrane Transport Proteins | 1 | 1995 | 4 | 0.010 |
Why?
|
| Cosmids | 1 | 1995 | 22 | 0.010 |
Why?
|
| Dextrorphan | 1 | 1994 | 1 | 0.010 |
Why?
|
| Levorphanol | 1 | 1994 | 2 | 0.010 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 1995 | 69 | 0.010 |
Why?
|
| Vanadates | 1 | 1995 | 32 | 0.010 |
Why?
|
| Thrombin | 1 | 1995 | 61 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 1995 | 47 | 0.010 |
Why?
|
| Amino Acid Transport Systems | 1 | 1994 | 4 | 0.010 |
Why?
|
| beta-Adrenergic Receptor Kinases | 1 | 1994 | 12 | 0.010 |
Why?
|
| Enkephalin, Leucine | 1 | 1994 | 6 | 0.010 |
Why?
|
| Biological Transport, Active | 1 | 1994 | 102 | 0.010 |
Why?
|
| Tritium | 1 | 1994 | 133 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 1994 | 62 | 0.010 |
Why?
|
| Cycloheximide | 1 | 1994 | 56 | 0.010 |
Why?
|
| Pigmentation | 1 | 1995 | 69 | 0.010 |
Why?
|
| Methionine | 1 | 1994 | 66 | 0.010 |
Why?
|
| Hydrogen Bonding | 1 | 1994 | 144 | 0.010 |
Why?
|
| Genes, src | 1 | 1993 | 6 | 0.010 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 1994 | 108 | 0.010 |
Why?
|
| Enkephalins | 1 | 1993 | 16 | 0.010 |
Why?
|
| Immunoblotting | 1 | 1994 | 272 | 0.010 |
Why?
|
| Epitopes | 1 | 1994 | 255 | 0.010 |
Why?
|
| Hepatoblastoma | 1 | 1993 | 12 | 0.010 |
Why?
|
| Cholesterol, LDL | 1 | 1995 | 223 | 0.010 |
Why?
|
| Antisense Elements (Genetics) | 1 | 1993 | 9 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 1993 | 65 | 0.010 |
Why?
|
| Cholic Acids | 1 | 1993 | 6 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 1994 | 210 | 0.010 |
Why?
|
| Detergents | 1 | 1993 | 34 | 0.010 |
Why?
|
| Niacin | 1 | 1993 | 37 | 0.010 |
Why?
|
| Dinucleoside Phosphates | 1 | 1993 | 9 | 0.010 |
Why?
|
| Ovary | 1 | 1995 | 261 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1993 | 137 | 0.010 |
Why?
|
| Narcotics | 1 | 1993 | 69 | 0.010 |
Why?
|
| Ion Channel Gating | 1 | 1996 | 324 | 0.010 |
Why?
|
| Pituitary Gland | 1 | 1993 | 117 | 0.010 |
Why?
|
| Growth Hormone | 1 | 1993 | 97 | 0.010 |
Why?
|
| Receptors, Dopamine | 1 | 1992 | 37 | 0.010 |
Why?
|
| Naltrexone | 1 | 1994 | 135 | 0.010 |
Why?
|
| Adipose Tissue, Brown | 1 | 1993 | 81 | 0.010 |
Why?
|
| Anterior Eye Segment | 1 | 1992 | 6 | 0.010 |
Why?
|
| Synapses | 1 | 1995 | 266 | 0.010 |
Why?
|
| WT1 Proteins | 1 | 1992 | 19 | 0.010 |
Why?
|
| Deoxyribonuclease I | 1 | 1992 | 28 | 0.010 |
Why?
|
| Ligands | 1 | 1994 | 437 | 0.010 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1993 | 151 | 0.010 |
Why?
|
| Estradiol | 1 | 1993 | 251 | 0.010 |
Why?
|
| Adenosine Deaminase | 1 | 1992 | 20 | 0.010 |
Why?
|
| Wilms Tumor | 1 | 1992 | 38 | 0.010 |
Why?
|
| Antibodies | 1 | 1994 | 353 | 0.010 |
Why?
|
| DNA Probes | 1 | 1992 | 77 | 0.010 |
Why?
|
| Perfusion | 1 | 1993 | 224 | 0.010 |
Why?
|
| Starvation | 1 | 1992 | 23 | 0.010 |
Why?
|
| Major Histocompatibility Complex | 1 | 1992 | 82 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 1994 | 459 | 0.010 |
Why?
|
| Dexamethasone | 1 | 1993 | 337 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 1993 | 442 | 0.010 |
Why?
|
| Dopamine | 1 | 1992 | 274 | 0.010 |
Why?
|
| Brain Mapping | 1 | 1994 | 562 | 0.010 |
Why?
|
| Fibroblasts | 1 | 1993 | 736 | 0.010 |
Why?
|
| Actins | 1 | 1993 | 454 | 0.010 |
Why?
|
| Software | 1 | 1994 | 657 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 1994 | 563 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 1995 | 3640 | 0.000 |
Why?
|
| Liver Neoplasms | 1 | 1993 | 759 | 0.000 |
Why?
|